Recombinant Human Adenovirus-p53 Injection Induced Apoptosis in Hepatocellular Carcinoma Cell Lines Mediated by p53-Fbxw7 Pathway, Which Controls c-Myc and Cyclin E
F-box and WD repeat domain-containing 7 (Fbxw7/hAgo/hCdc4/Fbw7) is a p53-dependent tumor suppressor and leads to ubiquitination-mediated suppression of several oncoproteins including c-Myc, cyclin E, Notch, c-Jun and others. Our previous study has indicated that low expression of Fbxw7 was negatively correlated with c-Myc, cyclin E and mutant-p53 in hepatocellular carcinoma (HCC) tissues. But the role and mechanisms of Fbxw7 in HCC are still unknown. Here, we investigated the function of Fbxw7 in HCC cell lines and the anti-tumor activity of recombinant human adenovirus-p53 injection (rAd-p53, Gendicine) administration in vitro and in vivo. Fbxw7-specific siRNA enhanced expression of c-Myc and cyclin E proteins and increased proliferation in cell culture. rAd-p53 inhibited tumor cell growth with Fbxw7 upregulation and c-Myc and cyclin E downregulation in vitro and a murine HCC model. This effect could be partially reverted using Fbxw7-specific siRNA. Here, we suggest that the activation of Fbxw7 by adenoviral delivery of p53 leads to increased proteasomal degradation of c-Myc and cyclin E enabling growth arrest and apoptosis. Addressing this pathway, we identified that rAd-p53 could be a potential therapeutic agent for HCC.
Wertz IE, Kusam S, Lam C, Okamoto T, Sandoval W et al. (2011) Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7. Nature 471: 110-114. doi:10.1038/nature09779. PubMed: 21368834.
[3]
Crusio KM, King B, Reavie LB, Aifantis I (2010) The ubiquitous nature of cancer: the role of the SCF (Fbw7) complex in development and transformation. Oncogene 29: 4865-4873. doi:10.1038/onc.2010.222. PubMed: 20543859.
[4]
Wang Z, Fukushima H, Gao D, Inuzuka H, Wan L et al. (2011) The two faces of FBW7 in cancer drug Resistance. Bioessays 33: 851-859. doi:10.1002/bies.201100101. PubMed: 22006825.
[5]
Tu K, Zheng X, Yin G, Zan X, Yao Y et al. (2012) Evaluation of Fbxw7 expression and its correlation with expression of SREBP-1 in a mouse model of NAFLD. Mol Med Report 6: 525-530.
[6]
Welcker M, Clurman BE (2008) FBW7 ubiquitin ligase: a tumour suppressor at the crossroads of cell division, growth and differentiation. Nat Rev Cancer 8: 83-93. doi:10.1038/nrc2290. PubMed: 18094723.
[7]
Tu K, Zheng X, Zan X, Han S, Yao Y et al. (2012) Evaluation of Fbxw7 expression and its correlation with the expression of c-Myc, cyclin E and p53 in human hepatocellular carcinoma. Hepatol Res 42: 904-910. doi:10.1111/j.1872-034X.2012.01005.x. PubMed: 22548670.
[8]
Hsu IC, Metcalf RA, Sun T, Welsh JA, Wang NJ et al. (1991) Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature 350: 427-428. doi:10.1038/350427a0. PubMed: 1849234.
[9]
Piao Z, Kim H, Jeon BK, Lee WJ, Park C (1997) Relationship beween loss of heterozygosity of tumor suppressor genes and histologic differentiation in hepatocellular carcinoma. Cancer 80: 865-872. doi:10.1002/(SICI)1097-0142(19970901)80:5. PubMed: 9307185.
[10]
Honda K, Sbisà E, Tullo A, Papeo PA, Saccone C et al. (1998) p53 mutation is a poor prognostic indicator for survival in patients with hepatocellular carcinoma undergoing surgical tumour ablation. Br J Cancer 77: 776-782. doi:10.1038/bjc.1998.126. PubMed: 9514057.
[11]
Mao JH, Perez-Losada J, Wu D, Delrosario R, Tsunematsu R et al. (2004) Fbxw7/Cdc4 is a p53-dependent, haploinsufficient tumour suppressor gene. Nature 432: 775-779. doi:10.1038/nature03155. PubMed: 15592418.
[12]
Yada M, Hatakeyama S, Kamura T, Nishiyama M, Tsunematsu R et al. (2004) Phosphorylation-dependent degradation of c-Myc is mediated by the F-box protein Fbw7. EMBO J 23: 2116-2125. doi:10.1038/sj.emboj.7600217. PubMed: 15103331.
[13]
Grandori C, Cowley SM, James LP, Eisenman RN (2000) The Myc/Max/Mad network and the transcriptional control of cell behavior. Annu Rev Cell Dev Biol 16: 653-699. doi:10.1146/annurev.cellbio.16.1.653. PubMed: 11031250.
[14]
Hwang HC, Clurman BE (2005) Cyclin E in normal and neoplastic cell cycles. Oncogene 24: 2776-2786. doi:10.1038/sj.onc.1208613. PubMed: 15838514.
[15]
Peng Z (2005) Current status of gendicine in China: recombinant human Ad-p53 agent for treatment of cancers. Hum Gene Ther 16: 1016-1027. doi:10.1089/hum.2005.16.1016. PubMed: 16149900.
[16]
Xie Q, Liang BL, Wu YH, Zhang J, Chen MW et al. (2012) Synergistic anticancer effect of rAd/P53 combined with 5-fluorouracil or iodized oil in the early therapeutic response of human colon cancer in vivo. Gene 499: 303-308. doi:10.1016/j.gene.2012.02.007. PubMed: 22441128.
[17]
Akhoondi S, Sun D, von der Lehr N, Apostolidou S, Klotz K et al. (2007) FBXW7/hCDC4 is a general tumor suppressor in human cancer. Cancer Res 67: 9006-9012. doi:10.1158/0008-5472.CAN-07-1320. PubMed: 17909001.
[18]
Bressac B, Kew M, Wands J, Ozturk M (1991) Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature 350: 429-431. doi:10.1038/350429a0. PubMed: 1672732.
[19]
Hayashi H, Sugio K, Matsumata T, Adachi E, Takenaka K et al. (1995) The clinical significance of p53 gene mutation in hepatocellular carcinomas from Japan. Hepatology 22: 1702-1707. doi:10.1002/hep.1840220614. PubMed: 7489977.
[20]
Li Y, Li LJ, Zhang ST, Wang LJ, Zhang Z et al. (2009) In vitro and clinical studies of gene therapy with recombinant human adenovirus-p53 injection for oral leukoplakia. Clin Cancer Res 15: 6724-6731. doi:10.1158/1078-0432.CCR-09-1296. PubMed: 19861457.
[21]
Kwak EL, Moberg KH, Wahrer DC, Quinn JE, Gilmore PM et al. (2005) Infrequent mutations of Archipelago (hAGO, hCDC4, Fbw7) in primary ovarian cancer. Gynecol Oncol 98: 124-128. doi:10.1016/j.ygyno.2005.04.007. PubMed: 15913747.
[22]
Ibusuki M, Yamamoto Y, Shinriki S, Ando Y, Iwase H (2011) Reduced expression of ubiquitin ligase FBXW7 mRNA is associated with poor prognosis in breast cancer patients. Cancer Sci 102: 439-445. doi:10.1111/j.1349-7006.2010.01801.x. PubMed: 21134077.
[23]
Iwatsuki M, Mimori K, Ishii H, Yokobori T, Takatsuno Y et al. (2010) Loss of FBXW7, a cell cycle regulating gene, in colorectal cancer: clinical significance. Int J Cancer 126: 1828–1837. PubMed: 19739118.
[24]
Yokobori T, Mimori K, Iwatsuki M, Ishii H, Onoyama I et al. (2009) p53-Altered FBXW7 expression determines poor prognosis in gastric cancer cases. Cancer Res 69: 3788-3794. doi:10.1158/0008-5472.CAN-08-2846. PubMed: 19366810.
[25]
Ohtsubo M, Theodoras AM, Schumacher J, Roberts JM, Pagano M (1995) Human cyclin E, a nuclear protein essential for the G1-to-S phase transition. Mol Cell Biol 15: 2612-2624. PubMed: 7739542.
[26]
Callens C, Baleydier F, Lengline E, Ben Abdelali R, Petit A et al. (2012) Clinical impact of NOTCH1 and/or FBXW7 mutations, FLASH deletion, and TCR status in pediatric T-cell lymphoblastic lymphoma. J Clin Oncol 30: 1966-1973. doi:10.1200/JCO.2011.39.7661. PubMed: 22547598.
[27]
Strohmaier H, Spruck CH, Kaiser P, Won KA, Sangfelt O et al. (2001) Human F-box protein hCdc4 targets cyclin E for proteolysis and is mutated in a breast cancer cell line. Nature 413: 316-322. doi:10.1038/35095076. PubMed: 11565034.
[28]
Haupt S, Berger M, Goldberg Z, Haupt Y (2003) Apoptosis - the p53 network. J Cell Sci 116: 4077-4085. doi:10.1242/jcs.00739. PubMed: 12972501.
[29]
Prendergast GC (1999) Mechanisms of apoptosis by c-Myc. Oncogene 18: 2967-2987. doi:10.1038/sj.onc.1202727. PubMed: 10378693.
